KR20150047510A - 미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린 - Google Patents
미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린 Download PDFInfo
- Publication number
- KR20150047510A KR20150047510A KR1020157005748A KR20157005748A KR20150047510A KR 20150047510 A KR20150047510 A KR 20150047510A KR 1020157005748 A KR1020157005748 A KR 1020157005748A KR 20157005748 A KR20157005748 A KR 20157005748A KR 20150047510 A KR20150047510 A KR 20150047510A
- Authority
- KR
- South Korea
- Prior art keywords
- deficiency
- mitochondrial
- microglobulin
- alpha
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201270538 | 2012-09-05 | ||
| DKPA201270538 | 2012-09-05 | ||
| DKPA201270557 | 2012-09-12 | ||
| DKPA201270557 | 2012-09-12 | ||
| PCT/EP2013/068270 WO2014037390A1 (en) | 2012-09-05 | 2013-09-04 | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150047510A true KR20150047510A (ko) | 2015-05-04 |
Family
ID=49162118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157005748A Ceased KR20150047510A (ko) | 2012-09-05 | 2013-09-04 | 미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10226507B2 (enExample) |
| EP (1) | EP2900254B1 (enExample) |
| JP (2) | JP2015533790A (enExample) |
| KR (1) | KR20150047510A (enExample) |
| CN (1) | CN104661673A (enExample) |
| AU (1) | AU2013311714C1 (enExample) |
| BR (1) | BR112015003957A2 (enExample) |
| CA (1) | CA2881321A1 (enExample) |
| DK (1) | DK2900254T3 (enExample) |
| EA (1) | EA028963B1 (enExample) |
| ES (1) | ES2599034T3 (enExample) |
| HR (1) | HRP20161364T1 (enExample) |
| HU (1) | HUE030559T2 (enExample) |
| IN (1) | IN2015DN00515A (enExample) |
| MX (1) | MX357656B (enExample) |
| NZ (1) | NZ629621A (enExample) |
| PL (1) | PL2900254T3 (enExample) |
| PT (1) | PT2900254T (enExample) |
| SG (1) | SG11201500669SA (enExample) |
| WO (1) | WO2014037390A1 (enExample) |
| ZA (1) | ZA201500547B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016204360A (ja) * | 2015-02-25 | 2016-12-08 | エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ | 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン |
| CA3014850A1 (en) * | 2016-02-25 | 2017-08-31 | A1M Pharma Ab | Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media |
| BR112018068522A2 (pt) * | 2016-03-18 | 2019-01-22 | A1M Pharma Ab | novas proteínas derivadas de alfa-1-microglobulina e seu uso |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| CN109867717A (zh) * | 2019-04-01 | 2019-06-11 | 山西瑞亚力生物技术有限公司 | 一种血浆中α1微球蛋白的提取方法 |
| CN110452980B (zh) * | 2019-09-23 | 2023-07-28 | 武汉儿童医院 | 一种线粒体脑肌病诊断试剂盒及应用 |
| US20220362293A1 (en) * | 2019-09-25 | 2022-11-17 | Cytegen Corp. | Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products |
| CN115575646B (zh) * | 2022-11-21 | 2023-04-28 | 四川大学华西医院 | 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0416906A (pt) * | 2003-11-26 | 2007-01-16 | Sanofi Aventis Deutschland | proteinúria tubular como um indicador para risco cardiovascular elevado |
| DK2111555T3 (da) * | 2007-02-12 | 2013-09-02 | A1M Pharma Ab | Diagnosticering af præeklampsi |
| SI2300614T1 (sl) * | 2008-02-04 | 2016-02-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Metode in sestavki za zdravljenje mitohondrijskih motenj |
| AU2009270435B2 (en) * | 2008-07-18 | 2014-10-16 | A1M Pharma Ab | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
-
2013
- 2013-09-04 HR HRP20161364TT patent/HRP20161364T1/hr unknown
- 2013-09-04 MX MX2015002604A patent/MX357656B/es active IP Right Grant
- 2013-09-04 KR KR1020157005748A patent/KR20150047510A/ko not_active Ceased
- 2013-09-04 EP EP13759995.7A patent/EP2900254B1/en not_active Not-in-force
- 2013-09-04 EA EA201590503A patent/EA028963B1/ru not_active IP Right Cessation
- 2013-09-04 AU AU2013311714A patent/AU2013311714C1/en not_active Ceased
- 2013-09-04 US US14/423,260 patent/US10226507B2/en not_active Expired - Fee Related
- 2013-09-04 IN IN515DEN2015 patent/IN2015DN00515A/en unknown
- 2013-09-04 CA CA2881321A patent/CA2881321A1/en not_active Abandoned
- 2013-09-04 WO PCT/EP2013/068270 patent/WO2014037390A1/en not_active Ceased
- 2013-09-04 HU HUE13759995A patent/HUE030559T2/en unknown
- 2013-09-04 DK DK13759995.7T patent/DK2900254T3/en active
- 2013-09-04 PL PL13759995T patent/PL2900254T3/pl unknown
- 2013-09-04 NZ NZ629621A patent/NZ629621A/en not_active IP Right Cessation
- 2013-09-04 JP JP2015530375A patent/JP2015533790A/ja active Pending
- 2013-09-04 PT PT137599957T patent/PT2900254T/pt unknown
- 2013-09-04 ES ES13759995.7T patent/ES2599034T3/es active Active
- 2013-09-04 SG SG11201500669SA patent/SG11201500669SA/en unknown
- 2013-09-04 CN CN201380043567.0A patent/CN104661673A/zh active Pending
- 2013-09-04 BR BR112015003957A patent/BR112015003957A2/pt not_active Application Discontinuation
-
2015
- 2015-01-23 ZA ZA2015/00547A patent/ZA201500547B/en unknown
-
2018
- 2018-08-24 JP JP2018157394A patent/JP2018203756A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201590503A1 (ru) | 2015-06-30 |
| JP2018203756A (ja) | 2018-12-27 |
| PT2900254T (pt) | 2016-10-18 |
| IN2015DN00515A (enExample) | 2015-06-26 |
| BR112015003957A2 (pt) | 2017-08-08 |
| DK2900254T3 (en) | 2016-08-29 |
| ES2599034T3 (es) | 2017-01-31 |
| HUE030559T2 (en) | 2017-05-29 |
| AU2013311714A1 (en) | 2015-03-12 |
| AU2013311714C1 (en) | 2018-01-25 |
| EA028963B1 (ru) | 2018-01-31 |
| AU2013311714B2 (en) | 2017-10-12 |
| ZA201500547B (en) | 2017-09-27 |
| WO2014037390A1 (en) | 2014-03-13 |
| PL2900254T3 (pl) | 2017-02-28 |
| HK1210585A1 (en) | 2016-04-29 |
| SG11201500669SA (en) | 2015-02-27 |
| US20150258171A1 (en) | 2015-09-17 |
| MX357656B (es) | 2018-07-18 |
| EP2900254B1 (en) | 2016-08-03 |
| MX2015002604A (es) | 2015-06-10 |
| NZ629621A (en) | 2015-09-25 |
| CA2881321A1 (en) | 2014-03-13 |
| EP2900254A1 (en) | 2015-08-05 |
| JP2015533790A (ja) | 2015-11-26 |
| CN104661673A (zh) | 2015-05-27 |
| US10226507B2 (en) | 2019-03-12 |
| HRP20161364T1 (hr) | 2016-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20150047510A (ko) | 미토콘드리아 관련 질환의 치료에서 사용하기 위한 알파-1-마이크로글로불린 | |
| Ebeling et al. | Improving retinal mitochondrial function as a treatment for age-related macular degeneration | |
| Uehara et al. | Auto-oxidation and oligomerization of protein S on the apoptotic cell surface is required for Mer tyrosine kinase-mediated phagocytosis of apoptotic cells | |
| Yin et al. | NDRG2 protects the brain from excitotoxicity by facilitating interstitial glutamate uptake | |
| Vigneswara et al. | Eye drop delivery of pigment epithelium-derived factor-34 promotes retinal ganglion cell neuroprotection and axon regeneration | |
| CN104023736A (zh) | Jnk信号转导途径的细胞-可渗透肽抑制剂用于治疗干眼综合征的用途 | |
| Wei et al. | Neuroglobin is an endogenous neuroprotectant for retinal ganglion cells against glaucomatous damage | |
| Gupta et al. | TrkB receptor agonist 7, 8 dihydroxyflavone is protective against the inner retinal deficits induced by experimental glaucoma | |
| JP2020501510A (ja) | 目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物 | |
| Gray et al. | N-terminal cleavage of the mitochondrial fusion GTPase OPA1 occurs via a caspase-independent mechanism in cerebellar granule neurons exposed to oxidative or nitrosative stress | |
| Lo et al. | Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2 | |
| Geng et al. | Mammalian STE20-like kinase 1 knockdown attenuates TNFα-mediated neurodegenerative disease by repressing the JNK pathway and mitochondrial stress | |
| JP2020536065A (ja) | 興奮性神経毒性に関連した損傷の治療用ペプチド組成物 | |
| Argenti | The role of mitochondrial dysfunction in Huntington's disease: pathogenesis and its relation with striatal Rhes protein | |
| Yang et al. | Glial cells activation potentially contributes to the upregulation of stromal cell-derived factor-1α after optic nerve crush in rats | |
| KR101567921B1 (ko) | Ｏｔｘ２ 단백질을 유효성분으로 포함하는 미토콘드리아 이상질환 예방 및 치료용 조성물 | |
| HK1210585B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
| KR102040893B1 (ko) | Arl6ip1의 유전성 강직성 하반신마비의 치료 용도 | |
| Li et al. | Protective effect of apelin-13 in lens epithelial cells via inhibiting oxidative stress-induced apoptosis | |
| Vijayasarathy et al. | Organization and molecular interactions of retinoschisin in photoreceptors | |
| Jones | The role of optic atrophy 1 (OPA1) in the evolution of brain damage after neonatal hypoxic-ischaemic insult | |
| KR20240155868A (ko) | 외상성 뇌손상의 치료 방법 | |
| CN106999579A (zh) | 可辨识致病性tdp‑43的抗体及其用途 | |
| Matthiessen et al. | Loss of ciliary proteins IFT20 and IFT88 results in defective phagocytosis and metabolism in the RPE | |
| Alassaf | Pregnancy Associated Plasma Protein-aa Is a Novel Regulator of Neuron Survival |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |